Cube Labs expands its own Portfolio with the creation of 5 NewCo’s selected and set up for the investment round of 2018.
The new Companies will be focusing the biotechnology market, innovative medical devices and AI solutions according with the most exciting and future trends in Life Sciences.
Personalized medicine and vital parameter analysis, molecules in the treatment of oncology and degenerative diseases, repositioning rescuing and synthesis of new molecules in the orphan disease, medtech and innovative solutions in critical heart conditions and cardiovascular are the core of the investment round.
Remaining firmly with our mission, we continue to focus on the growth of research and Italian excellence driving the science from research to the market of reference.
Just as year ago, December 2017 indeed had saw the foundation of 6 academic Spin Off that have brought uniqueness and competitiveness to our Holding in Life Science, the 2018 also successfully ends with a growth of our corporate Portfolio that currently counts 12 academic spin-offs.
Another fundamental milestone achieved from our A_team which qualifies and boost our path with concrete steps forward in 2019.